Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-22 receptor subunit alpha-2 (IL-22RA2)
- Target
- IL-22RA2
- Molecular classification
- Receptor (soluble/decoy, class II cytokine receptor family), Cytokine-binding protein
01
Overview
Interleukin-22 receptor subunit alpha-2 (IL-22RA2), also known as interleukin-22 binding protein (IL-22BP), is a secreted protein encoded by the IL22RA2 gene in humans. It acts as a soluble decoy receptor homolog, binding with high affinity to interleukin-22 (IL-22) and preventing its interaction with the membrane-bound IL-22 receptor (IL-22R1/IL-10R2 complex), thus inhibiting downstream signaling. IL-22RA2 is a member of the class II cytokine receptor family, lacks transmembrane and intracellular domains, and is mainly secreted by dendritic cells and epithelial cells in barrier tissues. By modulating IL-22 activity, IL-22RA2 plays a crucial role in the regulation of epithelial barrier homeostasis, inflammation, and tumorigenesis. Increased or dysregulated expression of IL-22RA2 has been associated with diseases such as inflammatory bowel disease and cancer[1][2][3][4][6].
- Other names
- Interleukin-22 binding proteinIL-22BPCRF2-S1
02
Mechanism of action
Antagonism of IL-22 signaling: binds IL-22 with high affinity, blocking its interaction with the cell-surface IL-22R1/IL-10R2 receptor complex[1][3][4]. Downregulation of IL-22-driven pathways in inflammation and cancer
03
Biological functions
Regulation of interleukin-22 (IL-22) activityImmune response regulationInhibition of IL-22-mediated signalingMaintenance of epithelial barrier homeostasisModulation of inflammation
04
Disease associations
InflammationCancer (tumorigenesis, especially in colon)Multisystem inflammatory syndrome in childrenInflammatory bowel diseaseAutoimmunity
05
Safety considerations
Therapeutic manipulation may risk immune dysregulation, impaired tissue repair, or increased susceptibility to infection (due to altered IL-22 activity); targeting IL-22BP requires careful monitoring[1][3].
06
Interacting drugs
None currently approved or widely used; IL-22/IL-22BP axis is being researched as a therapeutic target, but no specific inhibitors or drugs directly targeting IL-22RA2/IL-22BP are clinically established[3].
07
Biomarkers
Possible: levels of IL-22BP/IL-22RA2 in serum or tissues may serve as biomarkers for disease states involving IL-22 (e.g., inflammatory bowel disease, psoriasis), but clinical validation is incomplete[3].
Beyond the preview
Go deeper on Interleukin-22 receptor subunit alpha-2 (IL-22RA2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interleukin-22 receptor subunit alpha-2 (IL-22RA2).